Clinical stusy of induction S-1+Oxaliplatin+/-Cetuximab chemotherapy followed by short-course chemoradiotherapy in locally advanced ugly rectal cancer

Clinical stusy of induction S-1+Oxaliplatin+/-Cetuximab chemotherapy followed by short-course chemoradiotherapy in locally advanced ugly rectal cancer - Clinical stusy of induction S-1+Oxaliplatin+/-Cetuximab chemotherapy followed by short-course chemoradiotherapy in locally advanced ugly rectal cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017720

Enrollment

Registered

2015-06-01

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

locally advanced rectal cancer

Interventions

S-1/Oxaliplatin

treatment dose was decided by body mass index Cetuximab was used only Kras wild type

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) T3 lower rectal cancer with mesorectal fascia involvement 2) T4a or T4b tumors 3) lateral lymph node swelling with the cut-off size larger 5mm measured on axial view at shorter axis.

Exclusion criteria

Exclusion criteria: inflammatory bowel disease cardiac disease medical conditions that would not permit the patient to complete the study

Design outcomes

Primary

Measure	Time frame
pathologival complete response rate	—

Secondary

Measure	Time frame
Adverse event Compliance to induction chemotherapy R0 resection rate Down-staging rate(T,N stage) Tumor regression grade LFS; local recurrence free survival RFS; Recurrence free survival OS; Overall survival	—

Countries

Japan

Contacts

Public ContactNaohito Beppu

Meiwa Hospital Surgery

n_beppu@yahoo.co.jp+81-798-47-1767

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026